QPPV.COM KNOWLEDGE ASSESSMENT

Knowledge Assessment: CHMP Scientific Opinions and European Commission Marketing Authorisation Decisions

Test your understanding of the concepts covered by CHMP Scientific Opinions and European Commission Marketing Authorisation Decisions.

Question 1 of 10Pass mark: 80%

Question 1 of 10 A product has a conditional marketing authorisation. What conclusion follows from the article?

A positive CHMP opinion always produces an unrestricted standard authorisation. The product's specific authorisation type and conditions must be identified because they may affect regulatory and pharmacovigilance obligations. Conditional authorisations are scientific opinions rather than legal authorisations. Conditional status removes the need to monitor post-authorisation obligations.

Question 2 of 10 Which event establishes the legally operative Union marketing authorisation in the centralised procedure?

Completion of the applicant's original dossier Appointment of the rapporteurs Adoption of the CHMP assessment report Adoption of the applicable European Commission decision

Question 3 of 10 Why should the interval between a CHMP opinion and the Commission decision be retained in regulatory timelines?

It represents a formal transition from scientific assessment to legal decision-making. It proves that the applicant submitted a new marketing authorisation application. It is the period during which the CHMP repeats the entire assessment. It has no regulatory relevance once the CHMP opinion is positive.

Question 4 of 10 Which statement best explains why the CHMP scientific record remains important after the Commission has adopted the authorisation decision?

The CHMP record replaces the legal decision for all regulatory purposes. The CHMP record provides the scientific reasoning and benefit-risk context underlying the authorised conditions. The CHMP record determines current status even after a withdrawal. The CHMP record is needed only to calculate application fees.

Question 5 of 10 What is the significance of a negative CHMP opinion?

It is a scientific conclusion that the committee does not support granting the requested authorisation on the assessed application. It automatically proves that the Commission has adopted a final withdrawal decision. It is legally identical to a Commission refusal in every procedural circumstance. It has no effect because only applicant responses are considered by the Commission.

Question 6 of 10 Which statement best captures the relationship between scientific uncertainty and a CHMP opinion?

A formal opinion can be adopted only when every scientific uncertainty has been eliminated. The existence of uncertainty prevents the CHMP from reaching a collective conclusion. The CHMP can reach a formal collective scientific conclusion while acknowledging that some uncertainty remains. Uncertainty converts the opinion into an informal recommendation.

Question 7 of 10 A variation modifies the product information after the original Commission authorisation. How should the regulatory record describe the situation?

The original authorisation date alone remains sufficient to describe current status. The variation should be recorded as a subsequent regulatory event that may affect the current authorised terms. The CHMP opinion automatically becomes void. The product must be treated as unauthorised until a new initial application is submitted.

Question 8 of 10 Which statement best distinguishes the CHMP opinion from the European Commission decision in the centralised procedure?

The CHMP adopts the legally operative Union marketing authorisation, while the Commission performs the scientific assessment. The CHMP adopts a formal scientific opinion, while the Commission adopts the legally operative Union decision. The CHMP and Commission jointly sign a single marketing authorisation document. The Commission issues a non-binding scientific recommendation, while the CHMP grants the authorisation.

Question 9 of 10 A safety team is reconstructing whether an adverse reaction was listed in the reference safety information when an event occurred two years ago. Which approach is most appropriate?

Use the current product information because it represents the most complete knowledge. Use the product information and regulatory status applicable at the historical date, with effective dates and document versions. Use the date of the positive CHMP opinion regardless of later changes. Rely on the case narrative without consulting regulatory records.

Question 10 of 10 A product has additional pharmacovigilance activities and risk-minimisation measures linked to its authorisation. What is the most appropriate organisational response?

Treat them as voluntary activities because they arose from the scientific process. Maintain controlled records of the obligations and assign responsibility for implementation and oversight. Replace them with the company's standard safety procedures without assessment. Wait until a safety signal occurs before documenting them.

QPPV.com

Knowledge Assessment: CHMP Scientific Opinions and European Commission Marketing Authorisation Decisions

Cookie Settings